S&P Capital IQ: Recessionary Restraint

SP Capital IQ |

At this week’s investment policy committee meeting, we discussed how the duration and fragility of this economic recovery hints at a down 2013 for stocks.

We think the U.S. economy has four things going against it: 1) U.S. real GDP growth is typically weakest in year one of the presidential cycle, 2) come January, this recovery will be older than the average duration of all recoveries since 1900, 3) the S&P 500 recorded a median 9% decline whenever the first year of the four-year presidential cycle coincided with a recovery that was older than 20 months, and 4) the dire rhetoric surrounding the Fiscal Cliff negotiations is depressing investors’ confidence and is causing business leaders to delay hiring and expansion, thus threatening a harmful downdraft to this already low-flying recovery. But while history gives us reason to be cautious, we don’t believe the likeliest outcome of the Fiscal Cliff negotiations will be perpetual stalemate. Both Democrats and Republicans agree that they need to raise revenues and reduce debt. They just have yet to strike a compromise that will help them save face. We think they will find this solution before forcing our economy to endure a crash landing. Should the impasse in Congress cause the S&P 500 to decline this month, however, then the 2013 stock outlook would be increasingly tenuous. Since 1900, whenever the S&P 500 was up for the full year, yet ended on a down note by declining in December, the “500” posted an average return of minus 6.2% in the following year and fell more times than it rose. So let’s just hope that, in the end, Congress will be chanting “Ho, Ho, Ho,” rather than “No, No, No.”

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
NL NL Industries Inc. 3.98 -0.06 -1.49 61,970

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…